Search

Technetium Tc-99m oxidronate

[L1140] It was developed by Mallinkrodt nuclear and FDA approved on February 18, 1981.

Omega-3-carboxylic acids

[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386]

Prademagene zamikeracel

[L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

Chromic citrate

Hydromorphone

[A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]

Paliperidone

Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.

Mipomersen

It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity.

Dipyrithione

[L2611] It is currently used as a pesticide, and not used in any FDA approved drug products.

Balsam of Peru

[F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized

Lesinurad

In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with